Brazil Medical Device Registration Validity: 10 Years from DOU Publication

1. Key takeaways

The validity period of a Brazilian medical device registration is 10 years, and the starting point is the date of publication in the DOU — not the approval date and not the submission date — with consecutive revalidations possible. GRZAN’s judgment: the part most often misread is not the 10-year figure but the counting convention. Using the internal approval-letter date as the start date creates a systematic drift across the whole validity-management ledger. IVDs follow Article 12 of RDC 830/2023, also 10 years, but under a separate regulation, and the two sets of provisions must not be mixed when revalidating.

2. Legal basis

• Requirements for the classification, notification and registration of medical devices and for labeling and instructions for use — RDC nº 751/2022, resolution of September 15, 2022: Article 11 and Article 60(1)
• In vitro diagnostic medical devices — RDC nº 830/2023, published December 11, 2023 (DOU No. 234): Article 12
• Transfer of ownership and cancellation of product registrations — RDC nº 903/2024, published in the DOU on September 9, 2024: Article 29 (article numbers and key points compiled from multiple consistent sources; verify against the DOU or anvisalegis before final publication)

3. Expert insights

Why is the starting point the DOU publication date? GRZAN’s reading: in Brazil, an administrative act takes external effect upon publication in the federal official gazette (DOU), and Article 60(1) likewise uses DOU publication as the boundary that prohibits industrialization, import, display for sale, and delivery for consumption before it. Both provisions anchor on the same moment, and the design is internally consistent: the birth of the right (validity starting) and the lifting of the prohibition (marketability) must fall on the same instant. Otherwise you get gaps such as a certificate that is valid but unsellable, or a product that can be sold while the certificate has not yet started running, and the company’s internal ledger goes out of true with the law.

Companies commonly stumble in two ways. The first is building the ledger on the approval-letter date or the fee-payment date, which shifts every renewal reminder earlier or later; missing the revalidation window leaves the product unlicensed. The second is conflating medical devices with IVDs: the IVD validity rule sits in Article 12 of RDC 830/2023, which took effect on June 1, 2024 and belongs to a separate text from the device master regulation, so renewal documentation cannot be copied across.

One deadline convention must be stated precisely, and here lies a widely circulated citation error. For devices (Class III/IV registrations), the revalidation application must be filed before the registration expires, with a lead time of at most 12 months and at least 6 months. If ANVISA has not decided by the expiry date, revalidation is deemed automatic and the registration continues on its original conditions. The basis is Article 1 of RDC nº 250/2004 (as rewritten by RDC nº 212/2018), expressly referenced by Article 27(2) of RDC nº 751/2022. GRZAN cautions: these figures circulate widely in Chinese-language materials, but the source is often given as Article 8(2) of Decreto 8.077/2013 — that provision covers medicines and general health products. The numbers are right; the citation is wrong. Note also the boundary: Article 28 provides expressly that notification products are exempt from revalidation, so this window applies only to Classes III/IV; applying the early-renewal logic to Classes I/II is incorrect. For initiating the analysis, a CBPF acceptance receipt can stand in (Article 27(3)).

Digging one level deeper: the parent basis for this window is Article 12(6) of Lei nº 6.360/1976, but it states a relative formula — the first half of the last year of validity — which is hard-wired to the mother law’s 5-year validity. Device registrations run 10 years, so the formula cannot be applied directly; that is why Article 1 of RDC nº 250/2004 fixed it absolutely at 6–12 months, and why Article 27(2) of RDC nº 751/2022 points back to it. GRZAN cautions: devices must not cite Article 12(6) of the mother law directly — this is where many materials go astray. One more caution: automatic revalidation is not the same as passing. Article 1(1) of RDC nº 250/2004 states that a registration whose renewal application is overdue is declared lapsed (caducidade — not an automatic extension), and paragraph 3 states that automatic revalidation does not bar the review from continuing: ANVISA may still refuse and cancel a registration that has already been automatically renewed. GRZAN therefore reads treating automatic renewal as guaranteed passage at expiry as the second most frequent scheduling misjudgment. (Defer to ANVISA’s current consolidated texts.)

Another easily overlooked point: a transfer of ownership does not change the validity period. Under Article 29 of RDC 903/2024, a transfer preserves the product characteristics and the original validity, and the DOU publishes the new number and the cancellation of the old number simultaneously. GRZAN’s conclusion: a transfer brings no bonus of a fresh 10-year count, and treating it as a substitute for revalidation is wrong.

From a compliance-cost perspective, 10 years is a long window — long enough to cover most of a product’s life. GRZAN’s judgment: what truly demands management effort is not the revalidation in the final year but every change that occurs across the 10 years. Once the change ledger is disordered, restoring the product’s current state at revalidation costs far more than routine upkeep.

4. Practical recommendations

First, anchor the ledger on the DOU publication date. The GRZAN regulatory team recommends recording the DOU issue number and page for every registration individually, rather than the internal approval date.

Second, schedule renewals in tiers. Multi-product portfolios should be grouped by expiry year to avoid stacking documentation and fee pressure in a single year, and to avoid discovering only near expiry that the documentation has drifted from current regulations.

Third, link validity management with change management. For Classes III/IV, changes requiring approval take effect upon DOU publication, and immediate-implementation changes are published within 30 days of completed submission. The change cadence affects the documentation state at revalidation, so both belong on one calendar to keep the product’s current state reconstructable.

Fourth, no renewal by transfer. If the license-holding entity changes, follow RDC 903/2024 and inherit the original validity; do not count on a fresh start.

Fifth, run one unified calendar for multi-market portfolios. The same group often holds both Brazilian device and IVD registrations governed by different texts; GRZAN recommends a single calendar so neither expiry set is missed.

5. Verification checklist

• □ The DOU publication date of every registration number is recorded individually as the validity start point
• □ Devices apply Article 11 of RDC 751/2022 and IVDs Article 12 of RDC 830/2023, with no mixing of provisions
• □ Revalidation scheduling is grouped by expiry year with lead-time reminders set
• □ The change ledger and the validity ledger are managed in linkage
• □ Ownership-transfer projects confirm inheritance of the original validity, with the new and cancelled DOU numbers checked
• □ Device and IVD expiry milestones are consolidated in one unified calendar

Regulatory information verified as of October 29, 2026

GRZAN Regulatory Affairs Team

GRZAN supports manufacturers in the Brazilian market with ANVISA registration pathway and classification strategy work, including validity-ledger design, revalidation window management under RDC 250/2004 and RDC 751/2022, and change-control planning that keeps the dossier reconstruction-ready across a 10-year cycle. For a validity and renewal health check of your Brazil portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.